Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 1/2018

01-01-2018 | Original paper

Factors related to longitudinal adherence in colorectal cancer screening: qualitative research findings

Authors: Llucia Benito, Albert Farre, Gemma Binefa, Carmen Vidal, Angels Cardona, Margarita Pla, Montse García

Published in: Cancer Causes & Control | Issue 1/2018

Login to get access

Abstract

Background

The effectiveness of screening in colorectal cancer prevention depends on sustained participation rates. The objective of this study was to explore factors related to the longitudinal adherence of screening behavior in the context of a biennial population-based cancer screening program.

Methods

Eight focus groups were conducted with individuals who were invited two or three consecutive times to a population-based colorectal cancer screening program using a fecal occult blood test and who agreed to participate in the program at least once (n = 45). The criteria used to select the study members included adherence to fecal occult blood test maintenance, factors regarding their initial participation in the colorectal cancer screening, sex, and contextual educational level.

Results

The participants expressed a high level of satisfaction with the program; however, they showed a low level of understanding with respect to cancer screening. Consulting a general practitioner was cited by all participants as an important factor that mediated their final decision or influenced their behavior as a whole with regard to the program. Fear played a different role in the screening behavior for regular and irregular adherent participants. In the adherent participants, fear facilitated their continued participation in the screening program, whereas for the irregular participants, fear led them to avoid or refuse further screening. Having a close person diagnosed with colorectal cancer was a facilitator for the regular adherent participants. The irregular adherent participants showed some relaxation with respect to screening after a negative result and considered that further screening was no longer necessary.

Conclusion

Considering the importance of primary healthcare professionals in the decision regarding sustained participation, it is important to better engage them with cancer screening programs, as well as improve the communication channels to provide accurate and balanced information for both health professionals and individuals.
Literature
1.
Amonkar MM, Madhavan S, Rosenbluth SA, Simon KJ (1999) Barriers and facilitators to providing common preventive screening services in managed care settings. J Commun Health 24:229–247CrossRef
2.
Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, Parkin DM, Wardle J, Duffy SW, Cuzick J (2010) Once only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375:1624–1633CrossRefPubMed
3.
Beeker C, Kraft JM, Southwell BG, Jorgensen CM (2000) Colorectal cancer screening in older men and women: qualitative research findings and implications for intervention. J Commun Health 25:263–278CrossRef
4.
Braun V, Clarke V (2006) Using thematic analysis in psychology. Qual Res Psychol 3:77–101CrossRef
5.
Brenner H, Stock C, Hoffmeister M (2014) Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. Br Med J 348:g2467CrossRef
6.
Brenner H, Chang-Claude J, Jansen L, Knebel P, Stock C, Hoffmeister M (2014) Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. Gastroenterology 146:709–717CrossRefPubMed
7.
Bridou M, Aguerre C, Gimenes G, Kubiszewski V, Le Gall A, Potard C, Sorel O, Reveillere C (2013) Psychological barriers and facilitators of colorectal cancer screening: a french qualitative study. Health Psychol Res 1:e22CrossRefPubMedPubMedCentral
8.
Bulliard JL, De Landtsheer JP, Levi F (2004) Reattendance in the Swiss mammography screening pilot programme. J Med Screen 11:59Y64CrossRef
9.
Calazel-Benque A, Viguier J, Roussel C, Pivot X, Eisinger F, Blay JY, Coscas Y, Morère JF (2011) Organized colorectal cancer screening programmes: how to optimize efficiency in the general population. Eur J Cancer Prev 20:S20–S25CrossRefPubMed
10.
Clemow L, Costanza ME, Haddad WP, Luckmann R, White MJ, Klaus D, Stoddard AM (2000) Underutilizers of mammography screening today: characteristics of women planning, undecided about, and not planning a mammogram. Ann Behav Med 22:80–88CrossRefPubMed
11.
Commission of the European Communities (CEC) (2003) Proposal for a council recommendation on cancer screening. 2003/0093 (CNS). Commission of the European Communities (CEC), Brussels
12.
Crotta S, Segnan N, Paganin S, Dagnes B, Rosset R, Senore C (2012) High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol 10:633–638CrossRefPubMed
13.
Denis B, Gendre I, Perrin P (2015) Participation in four rounds of a French colorectal cancer screening programme with guaiac faecal occult blood test: a population-based open cohort study. J Med Screen 22:76–82CrossRefPubMed
14.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Canc 49:1374–1403CrossRef
15.
García M, Borràs JM, Milà N, Espinàs JA, Binefa G, Fernández E, Farré A, Pla M, Cardona A, Moreno V (2011) Factors associated with initial participation in a population-based screening for colorectal cancer in Catalonia, Spain: a mixed-methods study. Prev Med 52:265–267PubMed
16.
Gellad ZF, Stechuchak KM, Fisher DA, Olsen MK, McDuffie JR, Østbye T, Yancy WS (2011) Longitudinal adherence to fecal occult blood testing impacts colorectal cancer screening quality. Am J Gastroenterol 106:1125–1134CrossRefPubMed
17.
Glaser BG (1965) The constant comparative method of qualitative analysis. Soc Probl 5(12):436–445CrossRef
18.
Goel V, Gray R, Chart P, Fitch M, Saibil F, Zdanowicz Y (2004) Perspectives on colorectal cancer screening: a focus group study. Health Expect 7:51–60CrossRefPubMedPubMedCentral
19.
Grazzini G, Castiglione G, Ciabattoni C, Franceschini F, Giorgi D, Gozzi S, Mantellini P, Lopane P, Perco M, Rubeca T, Salvadori P, Visioli CB, Zappa M (2004) Colorectal cancer screening programme by faecal occult blood test in Tuscany: first round results. Eur J Cancer Prev 13:19–26CrossRefPubMed
20.
Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM (1996) Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348:1472–1477CrossRefPubMed
21.
Hewitson P, Glasziou P, Watson E, Towler B, Irwig L (2008) Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 103:1541–1549CrossRefPubMed
22.
Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JC, van der Togt AC, Habbema JD, Kuipers EJ (2010) Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 59:62–68CrossRefPubMed
23.
Honein-AbouHaidar GN, Kastner M, Vuong V, Perrier L, Daly C, Rabeneck L, Straus S, Baxter NN (2016) Systematic review and meta-study synthesis of qualitative studies evaluating facilitators and barriers to participation in colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 25:907–917CrossRefPubMed
24.
Jandorf L, Ellison J, Villagra C, Winkel G, Varela A, Quintero-Canetti Z, Castillo A, Thélémaque L, King S, Duhamel K (2010) Understanding the barriers and facilitators of colorectal cancer screening among low income immigrant Hispanics. J Immigr Minor Health 12:462–469CrossRefPubMedPubMedCentral
25.
Jones RM, Devers KJ, Kuzel AJ, Woolf SH (2010) Patient-reported barriers to colorectal cancer screening: a mixed-methods analysis. Am Journal Prev Me 38:508–516CrossRef
26.
Kapidzic A, Grobbee EJ, Hol L, van Roon AH, van Vuuren AJ, Spijker W, Izelaar K, van Ballegooijen M, Kuipers EJ, van Leerdam ME (2014) Attendance and yield over three rounds of population-based fecal immunochemical test screening. Am J Gastroenterol 109:1257–1264CrossRefPubMed
27.
Khalid-de Bakker C, Jonkers D, Smits K, Mesters I, Masclee A, Stockbrügger R (2011) Participation in colorectal cancer screening trials after first-time invitation: a systematic review. Endoscopy 43:1059–1086CrossRefPubMed
28.
Krönborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O (1996) Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348:1467–1471CrossRefPubMed
29.
Leuraud K, Jezewski-Serra D, Viguier J, Salines E (2013) Colorectal cancer screening by guaiac faecal occult blood test in France: Evaluation of the programme two years after launching. Cancer Epidemiol 37:959–967CrossRefPubMed
30.
31.
Lo SH, Halloran S, Snowball J, Seaman H, Wardle J, von Wagner C (2014) Colorectal cancer screening uptake over three biennial invitation rounds in the English bowel cancer screening programme. Gut 64:282–291CrossRefPubMedPubMedCentral
32.
Lo SH, Halloran S, Snowball J, Seaman H, Wardle J, Von Wagner C (2015) Predictors of repeat participation in the NHS bowel cancer screening programme. BJC 112:199–206CrossRefPubMed
33.
Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM (2000) The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 343:1603–1607CrossRefPubMed
34.
Marshall G (1994) A comparative study of re-attenders and non-re-attenders for second triennial National Breast Screening Programme appointments. J Public Health Med 16:79Y86CrossRef
35.
Maxwell A, Roshan B, Bradford C (1996) Predictors of interval mammography screening: results of a longitudinal study. J Womens Health 5:343Y349CrossRef
36.
37.
Milà N, García M, Binefa G, Borràs JM, Espinàs JA, Moreno V (2012) Adherence to a population-based colorectal cancer screening program in Catalonia (Spain), 2000–2008. Gac Sanit 26:217–222CrossRefPubMed
38.
Myers RE, Balshem AM, Wolf TA, Ross EA, Millner L (1993) Adherence to continuous screening for colorectal neoplasia. Med Care 31:508–519CrossRefPubMed
39.
40.
Nishihara R, Ogino S, Chan AT (2013) Colorectal-cancer incidence and mortality after screening. N Engl J Med 369:2355CrossRefPubMed
41.
42.
Orton M, Fitzpatrick R, Fuller A, Mant D, Mlynek C, Thorogood M (1991) Factors affecting women’s response to an invitation to attend for a second breast cancer screening examination. Br J Gen Pract 41:320Y322
43.
Palmer CK, Thomas MC, von Wagner C, Raine R (2014) Reasons for non-uptake and subsequent participation in the NHS Bowel Cancer Screening Programme: a qualitative study. Br J Cancer 110:1705–1711CrossRefPubMedPubMedCentral
44.
Panidi, Ksenia and Job Market. Ostrich effect in health care decisions: theory and empirical evidence. Diss. Dissertation (2014)
45.
Papin-Lefebvre F, Guillaume E, Moutel G, Launoy G, Berchi C (2017) General practitioners’ preferences with regard to colorectal cancer screening organisation Colon cancer screening medico-legal aspects. Health Policy 121:1079–1084
46.
Parkin DM, Tappenden P, Olsen AH, Patnick J, Sasieni P (2008) Predicting the impact of the screening programme for colorectal cancer in the UK. J Med Screen 15:163–174CrossRefPubMed
47.
Patton MQ (2002) Qualitative research and evaluation methods, 3rd edn. SAGE, London
48.
Peipins LA, Shapiro JA, Bobo JK, Berkowitz Z (2006) Impact of women’s experiences during mammography on adherence to rescreening (United States). Cancer Causes Control 17:439Y447CrossRef
49.
Peris M, Espinas JA, Muñoz L, Navarro M, Binefa G, Borras JM (2007) Lessons learnt from a population-based pilot program for colorectal cancer screening in Catalonia (Spain). J Med Screen 14:81–86CrossRefPubMed
50.
Ponti A, Anttila A, Ronco G, Senore C (2017) Cancer Screening in the European Union Report on the implementation of the Council Recommendation on cancer screening. Cancer screening in the European Union. Report on the implementation of the Council Recommendation on cancer screening (reprint May 2017)
51.
Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED, Fouad MN, Isaacs C, Johnson CC, Reding DJ, O’Brien B, Carrick DM, Wright P, Riley TL, Purdue MP, Izmirlian G, Kramer BS, Miller AB, Gohagan JK, Prorok PC, Berg CD, PLCO Project Team (2012) Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 366:2345–2357CrossRefPubMedPubMedCentral
52.
Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M, Andreoni B, Arrigoni A, Bisanti L, Casella C, Crosta C, Falcini F, Ferrero F, Giacomin A, Giuliani O, Santarelli A, Visioli CB, Zanetti R, Atkin WS, Senore C, SCORE Working Group (2011) Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial-SCORE. J Natl Cancer Inst. 103:1310–1322CrossRefPubMed
53.
Steele RJ, McClements PL, Libby G, Carey FA, Fraser CG (2014) Patterns of uptake in a biennial faecal occult blood test screening programme for colorectal cancer. Colorectal Dis 16:28–32CrossRefPubMed
54.
Tinmouth J, Lansdorp-Vogelaar I, Allison JE (2015) Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. Gut 64:1327–1337CrossRefPubMed
55.
van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E (2008) Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 135:82–90CrossRefPubMed
56.
van der Vlugt M, Grobbee EJ, Bossuyt PM, Bongers E, Spijker W, Kuipers EJ, Lansdorp-Vogelaar I, Essink-Bot ML, Spaander MC, Dekker E (2017) Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening. Br J Cancer 116:44–49CrossRefPubMed
57.
von Euler-Chelpin M, Brasso K, Lynge E (2010) Determinants of participation in colorectal cancer screening with faecal occult blood testing. J Public Health 32:395–405CrossRef
58.
von Karsa L, Anttila A, Ronco G, Ponti A, Malila N, Arbyn M, Segnan N, Castillo-Beltran M, Boniol M, Ferlay J, Hery C, Sauvaget C, Voti L, Autier P (2008) Cancer screening in the European Union. Report on the implementation of the Council Recommendation on Cancer Screening. International Agency for Research of Cancer, European Communities
59.
von Wagner C, Baio G, Raine R, Snowball J, Morris S, Atkin W, Obichere A, Handley G, Logan RF, Rainbow S, Smith S, Halloran S, Wardle J (2011) Inequalities in participation in an organized national colorectal cancer screening programme: results from the first 2.6 million invitations in England. Int J Epidemiol 40:712–718
60.
Vrinten C, Waller J, von Wagner C, Wardle J (2015) Cancer fear: facilitator and deterrent to participation in colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 24:400–405CrossRefPubMedPubMedCentral
61.
Weller DP, Patnick J, McIntosh HM, Dietrich AJ (2009) Uptake in cancer screening programmes. Lancet Oncol 10:693–699CrossRefPubMed
62.
Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG (1993) Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 85:1311–1318CrossRefPubMed
63.
Wong RK, Wong ML, Chan YH, Feng Z, Wai CT, Yeoh KG (2013) Gender differences in predictors of colorectal cancer screening uptake: a national cross-sectional study based on the health belief model. BMC Public Health 13:677–688CrossRefPubMedPubMedCentral
64.
Wools A, Dapper EA, de Leeuw JR (2016) Colorectal cancer screening participation: a systematic review. Eur J Public Health 26:158–168CrossRefPubMed
Metadata
Title
Factors related to longitudinal adherence in colorectal cancer screening: qualitative research findings
Authors
Llucia Benito
Albert Farre
Gemma Binefa
Carmen Vidal
Angels Cardona
Margarita Pla
Montse García
Publication date
01-01-2018
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 1/2018
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-017-0982-z

Other articles of this Issue 1/2018

Cancer Causes & Control 1/2018 Go to the issue

Original paper

Tree nut, peanut, and peanut butter intake and risk of postmenopausal breast cancer: The Netherlands Cohort Study

Brief report

Meat consumption and pancreatic cancer risk among men and women in the Cancer Prevention Study-II Nutrition Cohort

Original paper

A situational analysis of breast cancer early detection services in Trinidad and Tobago

Original paper

Fingernail and toenail clippings as a non-invasive measure of chronic cortisol levels in adult cancer survivors

Commentary

A framework to understand diet, physical activity, body weight, and cancer risk

Original paper

Uptake of HPV testing and extended cervical cancer screening intervals following cytology alone and Pap/HPV cotesting in women aged 30–65 years
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits